Download image

VM Loxapine

Visual representation of the interaction
Mode of action
Loxapine
Transporter zone
No interaction
Enzyme zone
No interaction
Receptor zone
Contributes to other effects
Important for clinical effects
Important for clinical effects
Contributes to other effects
Contributes to other effects
Ion channel zone
No interaction

NbN-2 loxapine

Molecular structure
NbN_library O N N N Cl
Mode of action
receptor antagonist (D2, 5-HT2)
Pharmacological target
dopamine, serotonin
Date published
05.01.2017

Loxapine

For more detailed explanation of the principles of the VM Library
For more detailed explanation of the Neuroscience based Nomenclature

Please notice that Caution should be applied when extrapolating animal data to humans.

Detailed and Approved Information on the clinical use of the compounds can be found at the homepage of EMA or at Martindale.

References
  1. Kapur S, Zipursky R, Remington G, et al. (1997) PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 154: 1525-1529.
  2. Kroeze WK, Hufeisen SJ, Popadak BA, et al. (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526.
  3. Popovic D, Nuss P and Vieta E. (2015) Revisiting loxapine: a systematic review. Ann Gen Psychiatry 14: 15.
  4. NbN-2 www.nbn2.com
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country